AI Article Synopsis
- Neuromuscular blocking agents (NMBAs) are crucial in anesthesia for procedures like intubation and mechanical ventilation, but they carry risks of acute complications, especially in patients with chronic kidney disease (CKD).
- A study used a large health database to compare the outcomes of two NMBAs - rocuronium with sugammadex and cisatracurium with neostigmine - in CKD patients, focusing on various complications within a week and mortality up to 30 days post-administration.
- The results showed that patients receiving rocuronium with sugammadex had significantly higher risks of respiratory failure, acute respiratory distress, hypertensive crisis, heart failure, pleural effusion, and a greater
Article Abstract
Background: Neuromuscular blocking agents (NMBAs) play an integral role in modern anesthesia by facilitating endotracheal tube placement, assisting with mechanical ventilation, and creating optimal surgical conditions. However, NMBAs can have deleterious side effects. The purpose of this study was to retrospectively analyze acute complications of 2 pharmacodynamically similar but pharmacokinetically different NMBAs and their respective reversal agents.
Methods: The global research network database, TriNetX, was used to evaluate deidentified patient information from 63 health care organizations. Cohort A was defined as patients aged 18 to 80 years who had chronic kidney disease (CKD) and were administered rocuronium with sugammadex. Cohort B was defined as patients aged 18 to 80 years who had CKD and were administered cisatracurium with neostigmine. Cohorts were propensity matched for age at event, ethnicity, race, sex, and relevant confounding pathologies. All outcomes besides mortality were analyzed from the same day to 1 week after administration of the indexed drug. Mortality was analyzed from the same day to thirty days after administration of the indexed drug.
Results: A total of 95,740 patients with CKD-administered rocuronium with sugammadex were matched with 10,708 patients with CKD-administered cisatracurium with neostigmine. Patients administered rocuronium with sugammadex had a significantly higher associated risk of respiratory failure (risk ratios [RR], 1.98, confidence interval [CI], 1.71-2.29, P < .0001), acute respiratory distress (RR, 2.70, CI, 1.31-5.58, P = .0052), hypertensive crisis (RR, 1.85, CI, 1.37-2.49, P < .0001), heart failure (RR, 1.14, CI, 1.06-1.23, P = .0004), pleural effusion (RR, 1.30, CI, 1.14-1.49, P < .0001), and 30-day mortality (RR, 1.31, CI, 1.10-1.56, P = .0021).
Conclusions: From 2003 to 2023, patients who were administered rocuronium plus sugammadex were at a significantly higher risk for acute cardiovascular and pulmonary complications when compared to patients who were administered cisatracurium plus neostigmine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1213/ANE.0000000000007188 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors Associated With Decision to Use and Dosing of Sugammadex in Children: A Retrospective Cross-Sectional Observational Study.
Anesth Analg
January 2025
From the Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan.
Background: Sugammadex was initially approved for reversal of neuromuscular blockade in adults in the United States in 2015. Limited data suggest sugammadex is widely used in pediatric anesthesia practice however the factors influencing use are not known. We explore patient, surgical, and institutional factors associated with the decision to use sugammadex versus neostigmine or no reversal, and the decision to use 2 mg/kg vs 4 mg/kg dosing.
View Article and Find Full Text PDFRepetition of sugammadex up to an equimolar dose in cases of accidental subcutaneous rocuronium administration.
Eur J Anaesthesiol
January 2025
From the Department of Internal and Emergency Medicine, Kantonsspital Aarau, Aarau (YAW) and Department of Anaesthesia and Critical Care Medicine, Buergerspital Solothurn, Solothurn, Switzerland (FM).
Sugammadex: A savior for an elderly cardiac patient! A case report.
Saudi J Anaesth
October 2024
Department of Anaesthesiology, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra, India.
In an elderly patient with known cardiac and pulmonary risk, a reversal agent with a faster onset and least hemodynamic effects is preferable. Being inert, the sugammadex-rocuronium complex is associated with minimal muscarinic effects. We report a successful management with rocuronium and sugammadex in an eighty three year old male patient with a history of Ischemic Heart Disease, atrial fibrillation, and Interstitial Lung Disease posted for a cochlear implant surgery.
View Article and Find Full Text PDFAnalysis of characteristics of patients whose sugammadex claims were denied by the Auto Insurance Claims Review Department of Korean Health Insurance Review & Assessment Service: a retrospective single-center review.
Anesth Pain Med (Seoul)
November 2024
Department of Anesthesiology and Pain Medicine, Chosun University Hospital, Gwangju, Korea.
Background: Recently, there have been many cases where sugammadex used in traffic accident patients has been deducted from auto insurance claims. This study aims to investigate the characteristics of sugammadex deductions through retrospective analysis.
Methods: We included patients who underwent general anesthesia after traffic accidents at our institution between January 2019 and December 2023.
Efficient Reversal of Neuromuscular Blocking Agent-Induced Biological Functions and Side Effects by an Extended Biphen[3]arene Carboxylate.
J Med Chem
December 2024
State Key Laboratory of National Security Specially Needed Medicines, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, P. R. China.
Article Synopsis
- * A new compound called ExBP3C was developed as an effective reversal agent for multiple NMBAs, showing strong binding capabilities with agents like atracurium and rocuronium.
- * ExBP3C demonstrated better efficiency than the existing reversal drug sugammadex, and in tests, it rapidly corrected heart rate issues caused by an overdose of atracurium within two minutes, indicating good safety and biocompatibility.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!